INTRODUCTION
The reduced diversity of the lung microbiome in respiratory conditions, including bronchiectasis, promotes bacterial infection and inflammation, contributing to worsening clinical outcomes. Traditional treatments often fail to address both infection and inflammation. Because of their potential dual-action,...
Stefania Glieca, Martina Tambassi, Chiara Schianchi et al.· Expert Opinion on Drug Deliv...· 0 citations
INTRODUCTION
Early-life respiratory infections may disrupt lung development during critical fetal, neonatal, and infant windows, when alveolarization, airway and vascular maturation, and immune programming remain active, potentially causing effects beyond the acute illness.
AREAS COVERED
This narrative review examine...
Susanna Esposito, Valentina Fainardi, N. Principi· Expert Review of Respiratory...· 0 citations
Human metapneumovirus (hMPV) is a major cause of acute lower respiratory tract infection in children, older adults, and individuals with underlying medical conditions. In pediatric populations, hMPV contributes substantially to hospitalizations, morbidity, and healthcare costs, yet no licensed vaccine or monoclonal ant...
Susanna Esposito, Valentina Fainardi, Gaia Giorgia Arnesano et al.· Frontiers in Immunology· 0 citations
Background: Antimicrobial resistance (AMR) is a major global health threat, while conventional diagnostic, stewardship, dosing, and drug-development strategies remain limited by diagnostic delays, population-level decision-making, and a shrinking antibiotic pipeline. Artificial intelligence (AI) may help address these...
